CTOs on the Move

US Micron

www.usmicron.com

 
US Micron is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.usmicron.com
  • 8704 Bourgade St Ste 200
    Lenexa, KS USA 66219
  • Phone: 913.888.7900

Executives

Name Title Contact Details

Similar Companies

Pharmacosmos

Pharmacosmos A/S is specialized in iron therapy. We develop, manufacture and market medicines for treatment of iron deficiency anaemia in humans and animals.

Hillsides

Hillsides is a premier provider dedicated to improving the overall well-being and functioning of vulnerable children, youth, and their families.

Centessa

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with a Research & Development innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. We are headquartered in Boston, Massachusetts.

Teva api

Teva api is an international pharmaceutical company headquartered in Israel.

Everest Medicines

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.